TY - JOUR
T1 - Genetic variant effects on gene expression in human pancreatic islets and their implications for T2D
AU - Viñuela, Ana
AU - Varshney, Arushi
AU - van de Bunt, Martijn
AU - Prasad, Rashmi B.
AU - Asplund, Olof
AU - Bennett, Amanda
AU - Boehnke, Michael
AU - Brown, Andrew A.
AU - Erdos, Michael R.
AU - Fadista, João
AU - Hansson, Ola
AU - Hatem, Gad
AU - Howald, Cédric
AU - Iyengar, Apoorva K.
AU - Johnson, Paul
AU - Krus, Ulrika
AU - MacDonald, Patrick E.
AU - Mahajan, Anubha
AU - Manning Fox, Jocelyn E.
AU - Narisu, Narisu
AU - Nylander, Vibe
AU - Orchard, Peter
AU - Oskolkov, Nikolay
AU - Panousis, Nikolaos I.
AU - Payne, Anthony
AU - Stitzel, Michael L.
AU - Vadlamudi, Swarooparani
AU - Welch, Ryan
AU - Collins, Francis S.
AU - Mohlke, Karen L.
AU - Gloyn, Anna L.
AU - Scott, Laura J.
AU - Dermitzakis, Emmanouil T.
AU - Groop, Leif
AU - Parker, Stephen C. J.
AU - McCarthy, Mark I.
N1 - Funding Information:
A.Vi. and E.T.D. were supported by EU IMI program (UE7-DIRECT-115317-1), NIH (NIH-R01-MH101814), and FNS funded project RNA1 (31003A_149984). A.Va. was supported by the American Association for University Women International Doctoral Fellowship, Barbour Doctoral Scholarship, and the University of Michigan Rackham Predoctoral Fellowship. M.v.d.B. was supported by a Novo Nordisk postdoctoral fellowship run in partnership with the University of Oxford. R.B.P. was supported by the EFSD/Novo Nordisk Programme for Diabetes Research in Europe, Diabetes Wellness (720-858-16 JDWG), Åke Wiberg Foundation (M18-0216). L.G. was supported by the Swedish Research Council project grant (2015-2558) Swedish Research Council, Astra Zeneca (10033731), Strategic Research Area Exodiab, Dnr 2009-1039, Swedish Foundation for Strategic Research Dnr IRC15-0067, and the Swedish Research Council, Linnaeus grant, Dnr 349-2006-237. F.S.C., M.R.E., and N.N. were supported by NHGRI-ZIA HG000024. A.K.I., S.V., and K.L.M. were supported by NIH R01 DK072193 and NIH U01 DK105561. S.C.J.P., L.J.S., and M.B. were supported by U01DK062370. M.L.S. was supported by K99/R00DK092251. P.O. was supported by grant T32 HG00040 from the National Human Genome Research Institute of the NIH. P.E.M. was supported by a Foundation grant from the Canadian Institutes of Health Research (CIHR: 148451). S.C. J.P. was supported by National Institute of Diabetes and Digestive and Kidney Diseases grants R00 DK-099240 and R01 DK-117960, American Diabetes Association Pathway to Stop Diabetes grant 1–14-INI-7. The Alberta Diabetes Institute IsletCore was supported by the Alberta Diabetes Foundation. We thank the Human Organ Procurement and Exchange (HOPE) program and the Trillium Gift of Life Network (TGLN) for their efforts in obtaining human organs for research. A.L.G. is a Wellcome Senior Fellow in Basic Biomedical Science. This work was funded in Oxford by the Wellcome Trust (095101, 200837, 106130, 203141, Medical Research Council (MR/L020149/1), European Union Horizon 2020 Programme (T2D Systems), NIH (U01-DK105535; U01-DK085545) and by the EU IMI program (UE7-DIRECT-115317-1). M.I.Mc.C was a Wellcome Senior Investigator and an NIHR Senior Investigator. He was supported by the Wellcome Trust (grants nos. 090532, 106130, 098381, 203141, and 212259); Medical Research Council grant no. MR/L020149/1; NIDDK (U01-DK105535, R01-MH101814, and R01-MH090941); NIHR (NF-SI-0617-10090). This work was also supported by the Oxford NIHR Biomedical Research Centre. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.
Funding Information:
M.I.M. has served on advisory panels for Pfizer, Novo Nordisk, and Zoe Global; received honoraria from Merck, Pfizer, Novo Nordisk, and Eli Lilly; and received research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Servier, and Takeda. As of June 2019, he is an employee of Genentech, and a holder of Roche stock. M.v.d.B. is an employee of Novo Nordisk A/S, although all experimental work was carried out under employment at the University of Oxford.
Publisher Copyright:
© 2020, The Author(s).
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/9/30
Y1 - 2020/9/30
N2 - Most signals detected by genome-wide association studies map to non-coding sequence and their tissue-specific effects influence transcriptional regulation. However, key tissues and cell-types required for functional inference are absent from large-scale resources. Here we explore the relationship between genetic variants influencing predisposition to type 2 diabetes (T2D) and related glycemic traits, and human pancreatic islet transcription using data from 420 donors. We find: (a) 7741 cis-eQTLs in islets with a replication rate across 44 GTEx tissues between 40% and 73%; (b) marked overlap between islet cis-eQTL signals and active regulatory sequences in islets, with reduced eQTL effect size observed in the stretch enhancers most strongly implicated in GWAS signal location; (c) enrichment of islet cis-eQTL signals with T2D risk variants identified in genome-wide association studies; and (d) colocalization between 47 islet cis-eQTLs and variants influencing T2D or glycemic traits, including DGKB and TCF7L2. Our findings illustrate the advantages of performing functional and regulatory studies in disease relevant tissues.
AB - Most signals detected by genome-wide association studies map to non-coding sequence and their tissue-specific effects influence transcriptional regulation. However, key tissues and cell-types required for functional inference are absent from large-scale resources. Here we explore the relationship between genetic variants influencing predisposition to type 2 diabetes (T2D) and related glycemic traits, and human pancreatic islet transcription using data from 420 donors. We find: (a) 7741 cis-eQTLs in islets with a replication rate across 44 GTEx tissues between 40% and 73%; (b) marked overlap between islet cis-eQTL signals and active regulatory sequences in islets, with reduced eQTL effect size observed in the stretch enhancers most strongly implicated in GWAS signal location; (c) enrichment of islet cis-eQTL signals with T2D risk variants identified in genome-wide association studies; and (d) colocalization between 47 islet cis-eQTLs and variants influencing T2D or glycemic traits, including DGKB and TCF7L2. Our findings illustrate the advantages of performing functional and regulatory studies in disease relevant tissues.
KW - Data acquisition
KW - Gene regulation
KW - Genetic association study
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85091718759&partnerID=8YFLogxK
U2 - 10.1038/s41467-020-18581-8
DO - 10.1038/s41467-020-18581-8
M3 - Article
C2 - 32999275
AN - SCOPUS:85091718759
SN - 2041-1723
VL - 11
JO - Nature Communications
JF - Nature Communications
M1 - 4912
ER -